Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kalaris Therapeutics's ebitda for the twelve months ending Dec 31, 2023 was -$199.50M. For fiscal 2023 it was -$199.50M. The highest annual figure on record is -$26.68M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$199.50M | – |
| FY2022 | Dec 31, 2022 | -$170.48M | – |
| FY2021 | Dec 31, 2021 | -$169.63M | – |
| FY2020 | Dec 31, 2020 | -$71.24M | – |
| FY2019 | Dec 31, 2019 | -$26.68M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$62.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$40.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$44.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$55.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.82M | – |
See a number that looks wrong?